Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Distinct antibody profile: a clue to primary antiphospholipid syndrome evolving into systemic lupus erythematosus?

Full text
Author(s):
Freire, Paula Vieira [1] ; Watanabe, Elisa [1] ; dos Santos, Nelita Rocha [1] ; Bueno, Cleonice [2] ; Bonfa, Eloisa [3] ; de Carvalho, Jozelio Freire [3, 4]
Total Authors: 6
Affiliation:
[1] Univ Santo Amaro, Sch Med, Sao Paulo - Brazil
[2] Univ Sao Paulo, Hosp Clin, Fac Med, Div Rheumatol, Med Res Lab, Sao Paulo - Brazil
[3] Univ Sao Paulo, Hosp Clin, Fac Med, Div Rheumatol, Sao Paulo - Brazil
[4] FMUSP, Disciplina Reumatol, BR-01246903 Sao Paulo - Brazil
Total Affiliations: 4
Document type: Journal article
Source: CLINICAL RHEUMATOLOGY; v. 33, n. 3, p. 349-353, MAR 2014.
Web of Science Citations: 7
Abstract

We have performed a retrospective study to determine if patients with antiphospholipid syndrome that developed systemic lupus erythematosus (APS/SLE) had distinct clinical and/or serological features. All 80 primary APS (PAPS) patients followed up at our APS unit were included in the study and divided into two groups: 14 APS/SLE and 66 PAPS. Prior or at onset of lupus manifestations, six patients were uniformly negative for lupus and Sjogren autoantibodies, and the other eight patients had persistent positive. In the first year after diagnosis of SLE, three patients remained with negative antibodies, the other seven patients maintained the same antibodies, and four patients developed other antibodies. APS/SLE group had a significant lower mean age at PAPS diagnosis (26.0 +/- 8.0 vs. 34.2 +/- 11.9 years, p = 0.03) and a longer disease duration (14.0 +/- 7.0 vs. 6.0 +/- 5.0 years, p < 0.0001). The mean time for PAPS to develop SLE was 5.2 +/- 4.3 years. The typical clinical and laboratorial findings of APS did not discriminate both groups of patients. At lupus onset, antinuclear antibodies were more frequently observed in those who evolved to SLE (100 vs. 51.5 %, p = 0.0005). Anti-double-stranded DNA (dsDNA), anti-ribosomal P, anti-Ro/SS-A, anti-La/SS-B, and anti-U1RNP antibodies were exclusively found in the APS/SLE patients, whereas anti-Smith (Sm) antibodies were not detected in both groups. The detection of a distinct subgroup of lupus-associated autoantibody in PAPS patients seems to be a hint to overt SLE disease, particularly in those patients with young age at diagnosis. (AU)